Talphera Inc. is a forward-thinking biotechnology company dedicated to creating pioneering peptide-based therapies for rare diseases and addressing significant unmet medical needs. With a promising pipeline concentrated on innovative cancer treatments and other high-need health sectors, Talphera is positioned for substantial growth. The company's commitment to research excellence combined with its focus on transformative healthcare solutions presents a compelling investment opportunity for institutional investors looking to capitalize on advancements in the biopharmaceutical landscape.
| Revenue (TTM) | 1,000 |
| Gross Profit (TTM) | -245,000 |
| EBITDA | $-15.16M |
| Operating Margin | -1451600.00% |
| Return on Equity | -118.40% |
| Return on Assets | -40.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.34 |
| Price-to-Book | 2.27 |
| Price-to-Sales (TTM) | 42303.40 |
| EV/Revenue | 20930.71 |
| EV/EBITDA | 0.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $51.90M |
| Float | $26.75M |
| % Insiders | 24.24% |
| % Institutions | 34.76% |
Volatility is currently contracting